Pharma Brand
When a major pharmaceutical company wanted to make sure its programmatic digital out of home impressions reached the right audience, OUTFRONT worked with our independent, third-party measurement partner, Crossix and our DSP partner Vistar. Together, we examined how effectively the campaign – advertising a new prescription drug for chronic obstructive pulmonary disorder (COPD) – reached the patients who needed it most.
58%
More Likely to Reach COPD Exacerbation Patients
Source
CROSSIX, 2024
CROSSIX, 2024
40%
More Likely to Reach Those Diagnosed with COPD
Source
CROSSIX, 2024
CROSSIX, 2024
25%
More Likely to Reach Core Maintenance Therapy Patients
Source
CROSSIX, 2024
CROSSIX, 2024
- Markets: Multiple markets
- Media Used: Digital Bulletins
- Campaign Duration: Six months, measured at midpoint
- Media Used: Digital Bulletins
- Campaign Duration: Six months, measured at midpoint
Highlights & Results
- The campaign was 58% more likely to reach patients diagnosed with COPD exacerbation than the general pharmacy-going population.
- The campaign was 40% more likely to reach those diagnosed with COPD.
- The campaign was 25% more likely to reach patients treating with core maintenance therapy.
DISCLAIMER: OF COURSE, THE RESULT OF ANY CASE STUDY ARE SPECIFIC TO ITS FACTS. WE CAN’T GUARANTEE THAT ANY OTHER CAMPAIGN WILL DRIVE SIMILAR RESULTS, INCLUDING INCREASED TRAFFIC, END-USER ACTIVITY (CLICK-THROUGH OR SECONDARY-ACTION RATES), OR REVENUE.
- The campaign was 40% more likely to reach those diagnosed with COPD.
- The campaign was 25% more likely to reach patients treating with core maintenance therapy.
DISCLAIMER: OF COURSE, THE RESULT OF ANY CASE STUDY ARE SPECIFIC TO ITS FACTS. WE CAN’T GUARANTEE THAT ANY OTHER CAMPAIGN WILL DRIVE SIMILAR RESULTS, INCLUDING INCREASED TRAFFIC, END-USER ACTIVITY (CLICK-THROUGH OR SECONDARY-ACTION RATES), OR REVENUE.